enGene Therapeutics ENGN
NASDAQ ENGN
$1.58 -0.05 (-3.07%)
At close: Oct 22, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Total Non-Current Liabilities (2022)

Updated

enGene Therapeutics (ENGN) posted Total Non-Current Liabilities of $89.07 million for fiscal Q4 2022 (quarter ended Oct 31, 2022).

Analysis

enGene Therapeutics (ENGN) Total Non-Current Liabilities (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 102.65 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 106.45 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 33.91 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn 35.10 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 97.04 Bn
10 enGene Therapeutics 105.88 Mn -888.59 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2022 89.07 Mn
API Access

enGene Therapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=ENGN&period=max&api_key=YOUR_API_KEY